Serum bilirubin levels are associated with poor functional outcomes in patients with acute ischemic stroke or transient ischemic attack

Quping Ouyang1,2†, Anxin Wang1,2†, Xue Tian3,4, Yingting Zuo3,4, Zhimeng Liu5, Qin Xu1,2, Xia Meng1,2, Pan Chen1,2, Hao Li1,2 and Yongjun Wang1,2*

Abstract

Background: The prognostic value of serum bilirubin in stroke is controversial, since bilirubin has both neuroprotective and neurotoxic properties. We aimed to investigate the association between serum bilirubin, including total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) and poor functional outcomes in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA).

Methods: All patients with AIS or TIA were recruited from the Third China National Stroke Registry. The poor functional outcomes included modified Rankin Scale (mRS) score 2–6 and 3–6 at 3 months and 1 year. Multivariable logistic regression was used to investigate the associations of TBIL, DBIL, and IBIL with poor functional outcomes.

Results: Among 11,121 enrolled patients, the median (interquartile range) of TBIL, DBIL, and IBIL was 13.30 (9.90–17.70), 3.80 (2.70–5.30), and 9.30 (6.70–12.80) µmol/L. After adjustment for conventional confounding factors, patients in the highest TBIL quartile had the highest proportion of mRS score 2–6 at 3 months (odds ratio [OR], 1.37; 95 % confidence interval [CI], 1.19–1.59) and 1 year (OR, 1.31; 95 % CI, 1.13–1.52), and mRS score 3–6 at 3 months (OR, 1.33; 95 % CI, 1.11–1.59) and 1 year (OR, 1.28; 95 % CI, 1.07–1.53), when compared to patients in the lowest TBIL quartile. Similar results were observed for DBIL and IBIL. We also found J-shaped associations between serum bilirubin levels and each outcome.

Conclusions: Elevated levels of serum bilirubin were significantly associated with poor functional outcomes in patients with AIS or TIA at 3 months and 1 year.

Keywords: Bilirubin, Prognosis, Poor functional outcomes, Acute ischemic stroke, Transient ischemic attack

* Correspondence: yongjunwang@ncrcnd.org.cn
† Quping Ouyang and Anxin Wang contributed equally to this work.
1 China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, 100070 Beijing, China
2 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Serum bilirubin is the end product of heme metabolism, it can exert both neuroprotective and neurotoxic effect on stroke through mechanisms involved in the development of ischemic stroke [1]. Nevertheless, conclusions derived from previous studies on the association between bilirubin and stroke prognosis were conflicting [2–9]. Some supported a positive association between serum bilirubin and poor functional outcomes, suggesting that serum bilirubin may be a highly toxic substance when high concentrations accumulated within biological tissues [2–5]. While other data supported a negative or a null significant association, suggesting that bilirubin harbors powerful antioxidant properties, higher levels of serum bilirubin might offer a therapeutic advantage in oxidative stress-mediated diseases, such as ischemic stroke [6–10]. This appear paradox between the strong basic evidence and the failure in translation to humans brings great confusion. Possible reasons for the discrepancy may be the small sample size in previous studies and the absence of long-term follow up.

We therefore conducted the current study to investigate the association of between serum bilirubin, including total bilirubin (TBIL), direct bilirubin (DBIL), and indirect bilirubin (IBIL), with poor functional outcomes in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA) using data from a large, long-term follow-up, prospective registry.

Materials and methods
Study population
Data were derived from the Third China National Stroke Registry (CNSR-III), which is a nationwide prospective registry for patients presented to hospitals with acute ischemic cerebrovascular events between August 2015 and March 2018 in China. Participants were consecutively enrolled if meeting the following criteria: (1) age 18 years or older; (2) diagnosis within 7 days of the index event of ischemic stroke or TIA; (3) informed consent from participant or legally authorized representative. The detailed, rationale, and basic description of the CNSR-III have been published previously [11]. A total of 15,166 patients were included from 201 hospitals of 22 provinces. The study protocol was approved by the ethics committee of all participating study centers according to the principles expressed in the Declaration of Helsinki. Written informed consent was provided by all participants or their legal proxies.

Baseline data collection
Trained research coordinators at each site collected baseline data through a direct interview or medical records, including age, sex, body mass index (BMI, calculated as the weight in kilograms divided by the square of the height in meters), smoking status, medical history, primary diagnosis, the aetiological classification conducted by the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) criteria [12], medication in hospital, and National Institutes of Health Stroke Scale (NIHSS) score.

Sample collection and measurement of serum bilirubin
Blood samples were collected within 24 h of admission. Plasma specimens were extracted, aliquoted and transported through cold chain to the central laboratory in Beijing Tiantan Hospital and stored at -80°C refrigerator until tests were performed centrally and blindly. TBIL, DBIL, IBIL, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), fasting blood glucose (FBG), serum creatinine, high-sensitivity C-reactive protein (hs-CRP), alanine aminotransferase (ALT), and aspartate aminotransferase (ALT) were tested in the central laboratory of Beijing Tiantan Hospital using Hitachi 7600 automatic biochemistry analyzer (Hitachi, Tokyo, Japan). The estimated glomerular filtration rate (eGFR) was calculated by Chronic Kidney Disease Epidemiology Collaboration equations [13].

Outcome assessment
Patients were followed up for clinical outcomes at 3 months and 1 year after symptom onset. They were interviewed face to face at 3 months and contacted over the telephone by trained research coordinators at 1 year. The poor functional outcomes included modified Rankin Scale (mRS) score 2–6/3–6 at 3 months and 1 year [14–16]. All events were collected by trained research coordinators who were blinded to subjects’ baseline characteristics.

Statistical analysis
Participants were classified into four groups by TBIL quartiles, DBIL quartiles, and IBIL quartiles, respectively. Continuous variables are presented as median (inter-quartile range [IQR]) because of the skewed distribution. Categorical variables are presented as frequency and percentage. The non-parametric Wilcoxon or Kruskal-Wallis tests is used to compare group differences for continuous variables and chi-square test is used for categorical variables.

Ordinal logistic regression was applied to estimate the common odds ratio (OR) for a shift in the direct of worse outcome on the mRS score according to serum bilirubin. The association between serum bilirubin and poor functional outcomes were assessed with multivariable binary logistic regression. Variables with P < 0.05 and the well-established predictors were selected as confounding variables in the multivariable analyses. The
| Variable                          | Overall               | Quartile of total bilirubin, μmol/L | P value |
|----------------------------------|-----------------------|-------------------------------------|---------|
|                                 | n                     | Q1(<9.90)  | Q2 (9.90-13.28) | Q3 (13.28-17.67) | Q4 (≥17.67) |
| Age, y                           | 63.00(54.00-70.00)    | 62.00(54.00-70.00) | 63.00(54.00-70.00) | 63.00(55.00-71.00) | 0.1924       |
| Men, n (%)                       | 7569 (68.06)          | 1676 (59.92) | 1793 (65.29) | 1967 (70.48) | 2133 (76.53) |
| BMI, kg/m²                       | 24.47(22.49-26.42)    | 24.34(22.49-26.35) | 24.44(22.58-26.37) | 24.49(22.26-26.49) | 24.49(22.49-26.45) |
| Current smoker                   | 3488 (31.36)          | 869 (31.07) | 862 (31.39) | 873 (31.28) | 884 (31.72) |
| Medical History, n (%)           | 6958 (62.57)          | 1765 (63.10) | 1717 (62.53) | 1727 (61.88) | 1749 (62.76) |
| Hypertension                     | 2572 (23.13)          | 751 (26.85) | 644 (23.45) | 640 (22.93) | 337 (11.95) |
| Dyslipidemia                     | 858 (7.72)            | 218 (7.79) | 227 (8.27) | 219 (7.85) | 194 (6.96) |
| Stroke or TIA                    | 76 (0.68)             | 25 (0.89) | 18 (0.66) | 17 (0.61) | 16 (0.57) |
| Heart failure                    | 68 (4.39)             | 12 (3.46) | 11 (3.09) | 19 (4.91) | 26 (5.68) |
| Stroke type/Subtype, n (%)       | 10339 (92.97)         | 2554 (91.31) | 2530 (92.13) | 2617 (93.77) | 2638 (94.65) |
| TOAST, n (%)                     | 782 (7.03)            | 243 (8.69) | 216 (7.87) | 174 (6.23) | 149 (5.35) |
| Large-artery atherosclerosis     | 2811 (25.28)          | 717 (25.63) | 674 (24.54) | 718 (25.73) | 702 (25.19) |
| Cardioembolism                   | 662 (5.95)            | 113 (4.04) | 130 (4.73) | 150 (5.37) | 269 (9.65) |
| Small-vessel occlusion           | 2319 (20.85)          | 578 (20.66) | 590 (21.49) | 627 (22.47) | 524 (18.80) |
| Other determined etiology        | 149 (1.34)            | 56 (2.00) | 26 (0.95) | 27 (0.97) | 40 (1.44) |
| Undetermined etiology            | 5180 (46.58)          | 1333 (47.66) | 1326 (48.29) | 1269 (45.47) | 1252 (44.92) |
| Medication in hospital, n (%)    | 10613 (96.12)         | 2656 (95.51) | 2629 (96.51) | 2650 (95.77) | 2678 (96.71) |
| Cholesterol-lowering agents      | 5052 (45.76)          | 1253 (45.06) | 1223 (44.90) | 1277 (46.15) | 1299 (46.91) |
| Antihypertensive agents          | 2751 (24.92)          | 747 (26.86) | 688 (25.26) | 696 (25.15) | 620 (22.39) |
| Hypoglycemic agents              | 10723 (97.12)         | 2730 (98.17) | 2662 (97.72) | 2679 (96.82) | 2652 (95.77) |
| Anticoagulant agents             | 1097 (9.94)           | 262 (9.42) | 229 (8.41) | 247 (8.93) | 359 (12.96) |
| NIHSS score on admission         | 3(1-6)                | 3(1-5) | 3(1-5) | 3(1-6) | 4(2-7) |
| Laboratory tests                 | TC, mmol/L            | 4.00(3.33-4.74) | 3.94(3.26-4.71) | 3.99(3.32-4.72) | 4.01(3.35-4.77) | 4.03(3.37-4.77) | 0.0412 |
|                                 | LDL, mmol/L           | 2.34(1.74-3.00) | 2.33(1.75-2.97) | 2.31(1.73-3.01) | 2.35(1.76-2.99) | 2.36(1.73-3.04) | 0.5899 |
|                                 | HDL, mmol/L           | 0.93(0.77-1.12) | 0.94(0.78-1.15) | 0.94(0.79-1.11) | 0.93(0.77-1.11) | 0.91(0.76-1.10) | 0.0028 |
|                                 | TG, mmol/L            | 1.36(1.03-1.87) | 1.29(0.99-1.74) | 1.33(1.02-1.82) | 1.42(1.06-1.95) | 1.44(1.09-2.02) | <0.0001 |
|                                 | FBG, mg/dl            | 5.51(4.89-688) | 5.51(4.89-689) | 5.50(4.89-681) | 5.53(4.90-695) | 5.51(4.88-682) | 0.5578 |
|                                 | eGFR, L/min•1.73 m²    | 92.99(81.39-101.75) | 93.72(79.48-102.24) | 92.62(80.80-101.14) | 93.06(82.93-101.74) | 92.73(82-101.91) | 0.2971 |
|                                 | hs-CRP, mg/L          | 1.76(0.80-4.71) | 1.75(0.86-4.63) | 1.64(0.77-4.25) | 1.72(0.79-4.53) | 1.90(0.82-5.72) | 0.0008 |
|                                 | ALT, U/L              | 18.00(13.00-25.80) | 17.00(12.00-24.00) | 18.00(13.00-25.00) | 18.00(13.00-25.00) | 19.00(14.00-27.00) | <0.0001 |
|                                 | AST, U/L              | 19.00(16.00-24.00) | 18.05(15.00-23.00) | 19.00(15.00-24.00) | 19.40(16.00-24.00) | 20.10(17.00-26.00) | <0.0001 |

Continuous variables are expressed as median with interquartile range. Categorical variables are expressed as frequency with percentage.

Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, eGFR estimated glomerular filtration rate, FBG fasting blood glucose, HDL high-density lipoprotein cholesterol, hs-CRP high sensitivity C-reactive protein, LDL low-density lipoprotein cholesterol, NIHSS The National Institutes of Health Stroke Scale, TC total cholesterol, TG triglycerides, TIA transient ischemic attack.
lowest quartile was defined as the reference group. Unadjusted and adjusted ORs and their 95% confidence intervals (CIs) were calculated. Because 201 hospitals participated in the study, the hospital was treated as clusters in the model and the sandwich estimated were used to account for the correlations. Trends tests were performed using quartiles as ordinal variables. In addition, we used restricted cubic splines to examine the shape of the association between bilirubin and outcomes with five knots (at the 5th, 25th, 50th, 75th, and 95th percentiles) [17]. Reference points for TBIL, DBIL, and IBIL were the median (8.10, 2.05, and 5.10 µmol/L, respectively) of the reference group (the lowest quartile) and OR was adjusted for variables in the multivariable analysis. Additionally, we used C statistics, integrated discrimination improvement (IDI), and net reclassification index (NRI) to evaluate the incremental predictive value of TBIL, DBIL, and IBIL beyond conventional risk factors. To test the robustness of the findings, sensitivity analysis was also performed by excluding patients with cardioembolism or TIA. Considering stroke severity at admission was a strong confounding factor the prognosis of stroke patients, subgroup analysis stratified by stroke severity measured by NIHSS Table 2 Adjusted odds ratio (95% confidence interval) for poor functional outcomes according to serum bilirubin levels

| Bilirubin | mRS score 2-6 | Quartiles | Events, n(%) | Unadjusted | Adjusted\(a\) | Events, n (%) | Unadjusted | Adjusted\(a\) |
|----------|----------------|-----------|--------------|------------|-------------|--------------|------------|-------------|
| TBIL     | Quartile 1     | 634 (22.67)| Reference    | Reference  | Reference 591 (21.13)| Reference  | Reference  |
|          | Quartile 2     | 692 (25.20)| 1.19(1.05-1.36)| 1.14(0.99-1.32)| 620 (22.58)| 1.14(0.99-1.30)| 1.09(0.95-1.26)|
|          | Quartile 3     | 759 (27.19)| 1.34(1.18-1.53)| 1.31(1.14-1.52)| 658 (23.58)| 1.21(1.06-1.39)| 1.17(1.01-1.35)|
|          | Quartile 4     | 860 (30.86)| 1.53(1.35-1.74)| 1.37(1.19-1.59)| 788 (28.27)| 1.51(1.32-1.72)| 1.31(1.13-1.52)|
|          | P for trend    | <0.0001    | <0.0001       | <0.0001    | <0.0001    | <0.0001      | <0.0001    | <0.0001     |
| mRS score 3-6 | Quartile 1    | 323 (11.55)| Reference    | Reference 319 (11.41)| Reference  | Reference  |
|          | Quartile 2     | 361 (13.15)| 1.19(1.01-1.41)| 1.13(0.95-1.36)| 338 (12.31)| 1.13(0.95-1.34)| 1.04(0.87-1.25)|
|          | Quartile 3     | 405 (14.51)| 1.35(1.14-1.59)| 1.29(1.08-1.54)| 370 (13.26)| 1.27(1.08-1.50)| 1.18(0.98-1.42)|
|          | Quartile 4     | 492 (17.65)| 1.58(1.35-1.86)| 1.33(1.11-1.59)| 471 (16.90)| 1.59(1.35-1.87)| 1.28(1.07-1.53)|
|          | P for trend    | <0.0001    | <0.0001       | <0.0001    | <0.0001    | <0.0001      | <0.0001    | <0.0001     |
| DBIL     | Quartile 1     | 625 (23.05)| Reference    | Reference 569 (20.98)| Reference  | Reference  |
|          | Quartile 2     | 701 (25.09)| 1.15(1.01-1.32)| 1.13(0.97-1.31)| 607 (21.73)| 1.10(0.96-1.26)| 1.05(0.90-1.22)|
|          | Quartile 3     | 766 (26.62)| 1.26(1.10-1.45)| 1.18(1.01-1.38)| 699 (24.30)| 1.33(1.15-1.53)| 1.21(1.04-1.42)|
|          | Quartile 4     | 853 (31.15)| 1.61(1.40-1.86)| 1.38(1.17-1.62)| 782 (28.56)| 1.69(1.47-1.95)| 1.37(1.17-1.61)|
|          | P for trend    | <0.0001    | <0.0001       | <0.0001    | <0.0001    | <0.0001      | <0.0001    | <0.0001     |
| mRS score 3-6 | Quartile 1    | 297 (10.95)| Reference    | Reference 284 (10.47)| Reference  | Reference  |
|          | Quartile 2     | 376 (13.46)| 1.33(1.12-1.59)| 1.29(1.07-1.56)| 336 (12.03)| 1.23(1.03-1.47)| 1.12(0.92-1.35)|
|          | Quartile 3     | 399 (13.87)| 1.39(1.16-1.66)| 1.29(1.06-1.56)| 390 (13.56)| 1.44(1.20-1.72)| 1.23(1.01-1.49)|
|          | Quartile 4     | 509 (18.59)| 1.98(1.66-2.37)| 1.59(1.30-1.94)| 488 (17.82)| 1.97(1.64-2.36)| 1.40(1.14-1.71)|
|          | P for trend    | <0.0001    | <0.0001       | <0.0001    | <0.0001    | <0.0001      | <0.0001    | <0.0001     |
| IBIL     | Quartile 1     | 641 (23.30)| Reference    | Reference 597 (21.70)| Reference  | Reference  |
|          | Quartile 2     | 709 (25.44)| 1.14(1.00-1.30)| 1.10(0.95-1.27)| 638 (22.89)| 1.07(0.94-1.22)| 1.03(0.90-1.20)|
|          | Quartile 3     | 769 (27.46)| 1.32(1.15-1.50)| 1.26(1.09-1.46)| 675 (24.11)| 1.19(1.04-1.36)| 1.13(0.97-1.31)|
|          | Quartile 4     | 826 (29.68)| 1.42(1.24-1.62)| 1.30(1.12-1.51)| 747 (26.84)| 1.35(1.18-1.55)| 1.21(1.04-1.41)|
|          | P for trend    | <0.0001    | <0.0001       | <0.0001    | <0.0001    | <0.0001      | <0.0001    | <0.0001     |

Abbreviations: DBIL direct bilirubin, IBIL indirect bilirubin, mRS modified Rankin Scale, TBIL total bilirubin
\(a\)Adjusted for age, sex, history of diabetes, atrial fibrillation/flutter, smoking status, stroke subtype, TOAST, hypoglycemic agents, antiplatelet agents, anticoagulant agents, baseline National Institutes of Health Stroke Scale score, total cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, alanine aminotransferase and aspartate aminotransferase
at baseline (NIHSS ≤ 3 for minor ischemic stroke and NIHSS > 3 for moderated to several ischemic stroke) was performed [18], interactions between subgroups were tested using likelihood ratio tests.

Overall, a two-sided $P < 0.05$ was considered statistically significant. All analyses were performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

**Results**

**Baseline characteristics**

Of 15,166 patients, 3,689 participants without TBIL, DBIL, and IBIL and 356 patients without available mRS score at 3 months or 1 year were excluded. Thus, a total of 11,121 patients were included in the final analysis. The baseline characteristics of included and excluded patients were well balanced, except that the included patients had a lower BMI, a higher prevalence of stroke or TIA, peripheral vascular disease and qualifying TIA, a higher proportion of use of cholesterol-lowering agents, antihypertensive agents, and a higher NIHSS, TC, LDL-C, and AST level (Table S1).

Among the 11,121 patients included, the median age was 63.00 years and 7,569 (68.06 %) patients were men. The median level of TBIL, DBIL, and IBIL was 13.30 (IQR, 9.90–17.70), 3.80 (IQR, 2.70–5.30), and 9.30 (IQR, 6.70–12.80) µmol/L. Baseline characteristics according to quartiles of TBIL is presented in Table 1. Compared with patients with lower TBIL, those with higher TBIL were more likely to be men, current smokers, had a higher prevalence of diabetes mellitus, atrial fibrillation/flutter, ischemic stroke, a lower proportion of use of hypoglycemic agents, antiplatelet agents, a higher proportion of use of anticoagulant agents, a higher NIHSS, TC, TG, hs-CRP, ALT, AST level and a lower level of HDL-C.

**Serum bilirubin and functional outcomes**

Poor functional outcome (mRS score 2–6) occurred in 2,945 (26.48 %) patients and mRS score 3–6 occurred in 1,581 (14.22 %) at 3 months. A mRS score 2–6 at 1 year assessment occurred in 2,657 patients (23.89 %) and a mRS score 3–6 occurred in 1,498 patients (12.47 %) (Table 2). There was significant shifts in the distribution of mRS score according to the levels of TBIL, DBIL, and IBIL (Fig. 1).

The associations of TBIL, DBIL, and IBIL with poor functional outcomes are presented in Table 2; Fig. 2. After adjustment for age, sex, history of diabetes, atrial fibrillation, smoking status, stroke subtype, hypoglycemic agents, antiplatelet agents, baseline National Institutes of Health Stroke Scale score, total cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, alanine aminotransferase and aspartate aminotransferase...
fibrillation/flutter, smoking status, stroke subtype, hypoglycemic agents, antithrombotic agents, baseline National Institutes of Health Stroke Scale score, total cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, alanine aminotransferase and aspartate aminotransferase.

Multivariable-adjusted spline regression models showed J-shaped associations of TBIL, DBIL, and IBIL levels with poor functional outcomes, including mRS score 2–6 and mRS score 3–6, at 3 months and 1 year follow-up (Figs. 3, 4 and 5).

**Incremental predictive value of bilirubin**

We evaluated whether TBIL, DBIL, and IBIL would further increase the predictive value of conventional risk factors (Table 3). For mRS score 2–6 at 3 months as the outcome of interest, the C statistics by the conventional model can significantly improve by addition of TBIL (from 0.762 to 0.763, \( P = 0.0437 \)). Furthermore, the discriminatory power and risk reclassification also appeared to substantially better, the IDI and category-free NRS was 2.07 % (95 % CI, 1.10-3.00 %, \( P < 0.0001 \)) and 8.56 % (95 % CI, 4.33-12.80 %, \( P < 0.0001 \)), respectively. Similar results were found for DBIL, IBIL, mRS score 3–6 as the outcome of interest, and when the time point was set as 1 year.

**Sensitivity and subgroup analysis**

Sensitivity analysis by excluding patients with cardioembolism or TIA showed consistent results with the main analysis (Table S2). Subgroup analysis for the association of serum bilirubin and poor functional outcomes...
stratified by stroke severity is shown in Table S2. The adjusted OR for the quartile 4 subgroup and mSR score 2–6 at 3 months was 1.13 (95% CI, 0.88–1.44) for minor ischemic stroke, and 1.52 (95% CI, 1.27–1.84) for moderate to severe ischemic stroke. However, there was no significant interaction between stroke severity and TBIL for the risk of mRS score 2–6 (P for interaction = 0.0938), indicating the association between TBIL and poor functional outcome was consistent across different stroke severity subgroups. The same results were observed for mRS score 3–6, when the time point was set as 1 year, and when DBIL or IBIL was the exposure.

Discussion
The main finding of this study was that higher levels of serum bilirubin, including TBIL, DBIL, and IBIL were all independently associated with poor functional outcomes in patients with AIS or TIA at 3 months and 1 year. These associations did not modified by stroke severity.

Evidence on the prognostic value of serum bilirubin in ischemic stroke is still controversial. The Acute Inflammatory Stroke Study with 142 stroke patients and the a cross-sectional prospective descriptive study with 275 ischemic stroke patients showed serum bilirubin level was significantly associated with mortality in the acute phase of ischemic stroke patients [4, 5]. Study of Kurzepa et al. with 43 patients reported that level of TBIL in the acute phase of ischemic stroke proved to be a bad prognostic factor for both early neurological status and for long term neurological functions measured at 3 months after stroke onset [2]. Similarly, a cross-sectional study conducted in Peshawar revealed that higher level of bilirubin was associated with increased poor functional outcomes measured by mRS score in patients with ischemic stroke [19]. This finding was also observed in the analysis on...
73 cases of large-artery atherosclerotic stroke, which indicated that the level of TBIL, DBIL, and IBIL was positively associated with poor functional outcomes on day 30 of hospitalization and discharge [3]. While not all previous studies supported the positive association between serum bilirubin and stroke prognosis. A cross-sectional study using data from the National Health and Nutrition Examination Survey showed per 1.71µmol/L (0.1 mg/dL) increment in TBIL was associated with a 10% reduced odds of an adverse stroke outcome among participants with a history of stroke. Not surprisingly, three studies even showed there was no significant association between levels of serum bilirubin and short-term clinical outcomes among patients with AIS [7–9].

Except the dual effect of serum bilirubin, other possible reasons for these inconsistent conclusions may include the research design, small sample size, as well as lack of long-term follow-up. To address these knowledge gaps and methodological limitations, we recruited patients with AIS or TIA from a large, prospective, and long-term study, which can provide more statistical power. Our results showed that higher levels of TBIL, DBIL, and IBIL were significantly associated with poor functional outcomes at 3 months and 1 year follow-up, the addition of bilirubin to the conventional risk model had an incremental on the predictive value for poor functional outcomes after ischemic stroke. The findings are in concordance with prior investigations regarding bilirubin as predictor of stroke and provide important insights into the relationship between bilirubin and stroke prognosis.

It was proposed serum bilirubin has also been reported to be associated with stroke severity at admission, which was a strong confounding factor influencing the prognosis of stroke patients, patients with severe stroke have a high risk of disabilities [20–22]. While our subgroup analysis stratified by stroke severity showed that there

![Multivariable-adjusted odds ratio and 95% confidence interval for (A) mRS score 2–6 at 3 months; B mRS score 3–6 at 3 months; C mRS score 2–6 at 1 year; and D mRS score 2–6 at 1 year by direct bilirubin level. Red lines represent the adjusted odds ratio and blue dash lines represent 95% confidence interval. Adjusted for age, sex, history of diabetes, atrial fibrillation/flutter, smoking status, stroke subtype, hypoglycemic agents, antiplatelet agents, baseline National Institutes of Health Stroke Scale score, total cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, alanine aminotransferase and aspartate aminotransferase.](image_url)
was no significant interaction between stroke severity and bilirubin in relation to the risk of poor functional outcomes of stroke, indicating the relationship between bilirubin and poor functional outcomes were consistent across different stroke severity subgroups, and that patients with minor and moderate to severe ischemic stroke had the same risk of poor functional outcomes with elevated bilirubin levels.

The plausible mechanisms responsible for the association between serum bilirubin and poor functional outcomes of stroke are summarized as follows. Bilirubin has both neuroprotective and neurotoxic capacities [1]. When bilirubin levels are in the normal range, it may act as an important endogenous anti-inflammatory and antioxidant molecule [23, 24]. Contrarily, pathological levels of bilirubin serve as an indicator of severe brain injury, a high concentration of unconjugated bilirubin can be cytotoxic, affecting the permeability of the mitochondrial membrane as well as damaging mitochondrial function and the activity of astrocytes, thereby resulting in neurocyte apoptosis [25–27]. After stroke occurs, the negative influence of high levels of serum bilirubin on patients’ outcome possibly reflects the intensity of initial oxidative stress. Patients with AIS or TIA with higher levels of bilirubin had larger cerebral infarcts, more prominent brain edema and more severe reperfusion injuries with poorer functional outcomes than those with lower bilirubin levels [3, 28].

The strengths of our study include that the study is a multicenter prospective registry with a large sample size, which resulted in sufficient statistical power. However, our study also had some limitations. First, this study only monitored the baseline bilirubin levels and did not examine the dynamic changes in bilirubin, which may have provided more valuable information regarding understand the mechanism underlying the associations.
Second, we excluded patients with missing data on serum bilirubin or mRS, which may lead to selection bias. Third, we did not record detailed information about the treatment on patients with impaired liver function. Specific treatment on patients with high bilirubin levels needed further investigations to explore. Finally, all patients were Chinese, this, our findings may not be generalizable to other races and ethnicities. Finally, some unmeasured or residual confounding effects may still exist because of the nature of the observational study.

### Conclusions

In conclusion, higher levels of bilirubin (TBIL, DBIL, and IBIL) were associated with poor functional outcomes in patients with AIS or TIA at 3 months and 1 year. This findings may promote the potential use of bilirubin in clinical practice as markers for stroke outcomes.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12883-021-02398-z.

### Additional file 1: Table S1.
Baseline characteristics of included and excluded patients. Table S2. Association between serum bilirubin and poor functional outcomes after excluding patients with cardioembolism or TIA. Table S3. Association between high serum bilirubin (quartile 4) and poor function outcomes stratified by stroke severity measured by NIHSS.

### Acknowledgements

We thank all the participating hospitals, their physicians and nurses, and CNSR III steering Committee members and all the participants in the present study.

### Authors’ contributions

YW contributed to the conception of this work. OQ and AW made substantial contributions to study design, data collection, data analysis and manuscript writing. XT, YZ, ZL, and QX made substantial contributions to study design and intellectual direction. XM, PC, and HL made contributions to data collection. All authors read and approved the final manuscript.

---

**Table 3** Reclassification and discrimination statistics for outcomes within 90 days and 1 year by serum bilirubin

| Outcomes at 3 months | C statistic | IDI | Category-free NRI |
|----------------------|------------|-----|--------------------|
|                      | Estimate (95% CI) | P value | Estimate (95% CI), % | P value | Estimate (95% CI), % | P value |
|                      |                        |        | Reference           |         | Reference           |         |
| mRS score 2-6        | 0.762(0.752-0.772)    | 0.0437 | 2.07(1.10-3.00)     | <0.0001 | 8.56(4.33-12.80)    | <0.0001 |
| Conventional model+TBIL | 0.763(0.753-0.773) | 0.1089 | 2.12(1.20-3.10)     | <0.0001 | 8.43(4.18-12.68)    | 0.0001  |
| Conventional model+DBIL | 0.763(0.753-0.773) | 0.0443 | 1.52(0.07-2.40)     | 0.0004  | 7.17(2.94-11.41)    | 0.0010  |
| mRS score 3-6        | 0.780(0.768-0.792)    | 0.0252 | 2.44(1.10-3.70)     | 0.0003  | 10.53(5.15-15.90)   | 0.0001  |
| Conventional model+TBIL | 0.782(0.770-0.794) | 0.0432 | 4.50(2.70-6.30)     | <0.0001 | 10.56(5.18-15.95)   | 0.0001  |
| Conventional model+DBIL | 0.782(0.770-0.794) | 0.0311 | 1.18(0.20-2.10)     | 0.0138  | 8.03(2.66-13.40)    | 0.0037  |

**Abbreviations:** CI confidence interval, DBIL direct bilirubin, IBIL indirect bilirubin, IDI integrated discrimination improvement, mRS modified Rankin Scale, NRI net reclassification index, TBIL total bilirubin

*Adjusted for age, sex, history of diabetes, atrial fibrillation/flutter, smoking status, stroke subtype, hypoglycemic agents, antiplatelet agents, baseline National Institutes of Health Stroke Scale score, total cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitivity C-reactive protein, alanine aminotransferase and aspartate aminotransferase
Funding
This work was supported by National Natural Science Foundation of China (81870905, U20A20358), Beijing Municipal Science & Technology Commission (D171100003017002), Beijing Municipal Administration of Hospitals Incubating Program (PX2020021), and Beijing Excellent Talents Training Program (201800021469G294).

Availability of data and materials
Data are available to researchers on request for purposes of reproducing the results or replicating the procedure by directly contacting the corresponding author.

Declarations

Ethics approval and consent to participate
The study was approved by the ethics committee of Beijing Tiantan Hospital (No. KY2015-001-01) and all study centers gave ethical approval of the study protocol. Written consents were obtained from all participants or their legal representatives.

Consent for publication
Not applicable.

Competing interests
The authors report no disclosures relevant to the manuscript.

Author details
1China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, 100070 Beijing, China. 2Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 3Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China. 4Department of Biostatistics in Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, North Carolina, USA.

Received: 4 July 2021 Accepted: 13 September 2021

Published online: 27 September 2021

References
1. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci U S A. 2009;106(13):5171–6. https://doi.org/10.1073/pnas.0813132106.

2. Kurzepa J, Bielewicz J, Stelmasiak Z, Bartosik-Psujek H. Serum bilirubin and uric acid levels as the bad prognostic factors in the ischemic stroke. Int J Neurosci. 2009;119(12):2243–9. https://doi.org/10.3109/0020745090323939.

3. Wang Y, Xu S, Pan S, Ouyang H, Zang Z, Tan J. Association of serum bilirubin with ischemic stroke outcomes. J Stroke Cerebrovasc Dis. 2008;17:3147–52. https://doi.org/10.1016/j.jstrokecerebrovascdis.2008.01.009.

9. Bhatia RS, Garg RK, Gaur SP, Kar AM, Shukla R, Agarwal A, et al. Predictive value of routine hematological and biochemical parameters on 30-day fatality in acute stroke. Neurology India. 2004;52(2):220–3.

10. Zhong P, Wu D, Ye X, Wang X, Zhou Y, Zhu X, et al. Association of circulating total bilirubin level with ischemic stroke: a systemic review and meta-analysis of observational evidence. Ann Transl Med. 2019;7(14):335. https://doi.org/10.21037/atm.2019.06.71.

11. Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X, et al. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke Vasc Neurol. 2019;4(3):158–64. https://doi.org/10.1136/svn-2019-000242.

12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. https://doi.org/10.1161/01.str.24.1.35.

13. Inker LA, Astor BC, Fox CH, Isaakova T, Lash JP, Penna CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35. https://doi.org/10.1053/j.ajkd.2014.01.416.

14. Wang A, Zhang X, Li S, Zhao X, Liu L, Johnston SC, et al. Oxidative lipoprotein markers predict poor functional outcome in patients with minor stroke or transient ischemic attack. Eur J Neurol. 2019;26(B8):1082–90. https://doi.org/10.1111/ene.13943.

15. Wang A, Tian X, Gu H, Zuo Y, Meng X, Lv W, et al. CO2 combining power and outcomes in patients with acute ischaemic stroke or transient ischaemic attack. Stroke Vasc Neurol. 2020. https://doi.org/10.1136/svn-2020-000476.

16. Schonewille WJ, Algra A, Serena J, Molina CA, Kappelle LJ. Outcome in patients with basilar artery occlusion treated conventionally. J Neurol Neurosurg Psychiatry. 2005;76(9):1238–41. https://doi.org/10.1136/jnnp.2004.049924.

17. Singh K, Chandra A, Sperry T, Joshi PK, Khaira A, Vinasi SS, et al. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020;142(7):657–69. https://doi.org/10.1161/circulationaha.120.045713.

18. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale Score strongly predicts outcomes after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53(1):126–31. https://doi.org/10.1212/wnl.53.1.126.

19. Arsalan, Ismail M, Khattak MB, Khan F, Anwar MJ, Murtaza Z, et al. Prognostic significance of serum bilirubin in stroke. J Ayub Medical Coll Abbottabad. 2011;29(2):104–7.

20. Luo Y, Li J, Zhang J, Xu Y. Elevated bilirubin after acute ischemic stroke linked to the stroke severity. Int J Dev Neurosci. 2013;31(7):634–8. https://doi.org/10.1016/j.jidneu.2013.08.002.

21. Abubakar SA, Okubadejo NU, Ojo OO, Oladipo O, Ojini FI, Danesi MA. Relationship between admission serum C-reactive protein and short term outcome following acute ischaemic stroke at a tertiary health institution in Nigeria. Nigerian J Clin Pract. 2013;16(3):320–4. https://doi.org/10.4103/1119-3077.113454.

22. Luo Y, Li JW, Lu ZJ, Wang C, Guan DN, Xu Y. Serum bilirubin after acute ischemic stroke is associated with stroke severity. Curr Neurovasc Res. 2012;9(2):128–32. https://doi.org/10.2174/156720212800410876.

23. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vascul Med. 2002;7(3):195–202. https://doi.org/10.1177/1547185901011305.

24. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006;184(2):431–7. https://doi.org/10.1016/j.atherosclerosis.2005.05.011.

25. Mendez NV, Abdulla MA, Leckler J, Blackburn SL, Douglas-Escobar MV, Weiss MD, et al. Clinical Implications of Bilirubin-Associated Neuroprotection and Neurotoxicity. Int J Clin Anesthesiol. 2013;1:2.

26. Rodrigues CM, Solà S, Silva R, Brites D. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol Med. 2006;11(1):936–46.

27. Orozco-Ibarra M, Estrada-Sánchez AM, Massieu L, Pedraza-Chaverri J. Heme oxygenase-1 induction prevents neuronal damage triggered during...
mitochondrial inhibition: role of CO and bilirubin. Int J Biochem Cell Biol. 2009;41(6):1304–14. https://doi.org/10.1016/j.biocel.2008.11.003.

28. Wang X, Wu D, Zhong P. Serum bilirubin and ischaemic stroke: a review of literature. Stroke Vasc Neurol. 2020;5(2):198–204. https://doi.org/10.1136/svn-2019-000289.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.